MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584498 | Name: Ruscogenin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ruscogenin is a steroid sapogenin that has been found in O. japonicus with diverse biological activities and prevents monocrotaline-induced increases in mean arterial pressure (MAP), expression of IL-1β and TNF in plasma and lung, and endothelial cell apoptosis in pulmonary arterioles in a rat model of pulmonary hypertension.

Chemical Structure

Ruscogenin
Ruscogenin
CAS#472-11-7

Theoretical Analysis

MedKoo Cat#: 584498

Name: Ruscogenin

CAS#: 472-11-7

Chemical Formula: C27H42O4

Exact Mass: 430.3083

Molecular Weight: 430.63

Elemental Analysis: C, 75.31; H, 9.83; O, 14.86

Price and Availability

Size Price Availability Quantity
1mg USD 250.00
5mg USD 500.00
10mg USD 800.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ruscogenin
IUPAC/Chemical Name
(1beta,3beta,25R)-spirost-5-ene-1,3-diol
InChi Key
QMQIQBOGXYYATH-IDABPMKMSA-N
InChi Code
InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1
SMILES Code
[H][C@]1(O[C@@]2(OC[C@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC=C6C[C@@H](O)C[C@@H](O)[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, DMF, and ethanol
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ruscogenin exhibits diverse biological activities. It reduces cell adhesion of HL-60 cells to ECV304 cells induced by PMA (phorbol 12-myristate 13-acetate) with an IC50 value of 7.76 nM. Ruscogenin inhibits ADP-induced platelet aggregation in rats when administered orally at a dose of 12.5 mg/kg.
In vitro activity:
Ruscogenin suppresses hepatic cell injury induced by oxidative stress through Nrf2 via activation of the pI3K/AKT signaling pathway. Ruscogenin pretreatment downregulated the expression of DON-induced TNF-α and COX-2 and ROS formation. Ruscogenin upregulated the expression of Nrf2, its antioxidant proteins, and mRNA levels of HO-1/NQO-1/HO-1/Nrf2. Ruscogenin inhibited DON-induced apoptosis by upregulating the levels of cleaved proteins and downregulating the expression of Bcl2. Reference: Saudi J Med Med Sci. 2022 Sep-Dec;10(3):207-215. https://pubmed.ncbi.nlm.nih.gov/36247053/
In vivo activity:
Ruscogenin demonstrated a significant reduction in cerebral infarct volume, improved behavioral scores, and upregulated the protein expression of Per1, Bmal1, Clock, Rev-erbα, transcription factor nuclear factor erythroid 2-related factor 2, heme oxygenase-1, and quinone oxidoreductase 1 in a mouse model of cerebral ischemia-reperfusion injury (IRI). Ruscogenin administration during the 17:00-19:00 time window exhibited the most potent preventive effect against IRI. Reference: Phytomedicine. 2023 Aug 20;120:155028. https://pubmed.ncbi.nlm.nih.gov/37659295/
Solvent mg/mL mM
Solubility
DMF 10.0 23.22
DMSO 10.0 23.22
Ethanol 2.0 4.64
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 430.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Elsawy H, Rajendran P, Sedky AM, Alfwuaires M. Ruscogenin Protects Against Deoxynivalenol-Induced Hepatic Injury by Inhibiting Oxidative Stress, Inflammation, and Apoptosis Through the Nrf2 Signaling Pathway: An In vitro Study. Saudi J Med Med Sci. 2022 Sep-Dec;10(3):207-215. doi: 10.4103/sjmms.sjmms_725_21. Epub 2022 Aug 22. PMID: 36247053; PMCID: PMC9555037. 2. Song Z, Xiang X, Li J, Deng J, Fang Z, Zhang L, Xiong J. Ruscogenin induces ferroptosis in pancreatic cancer cells. Oncol Rep. 2020 Feb;43(2):516-524. doi: 10.3892/or.2019.7425. Epub 2019 Dec 10. PMID: 31894321; PMCID: PMC6967081. 3. Zhang S, Yu Y, Sheng M, Chen X, Wu Q, Kou J, Chen G. Ruscogenin timing administration mitigates cerebral ischemia-reperfusion injury through regulating circadian genes and activating Nrf2 pathway. Phytomedicine. 2023 Aug 20;120:155028. doi: 10.1016/j.phymed.2023.155028. Epub ahead of print. PMID: 37659295. 4. Huang J, Zhou J, Dai Y, Liu Y, Li F, Gong S, Zhang Y, Kou J. Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways. J Nat Med. 2023 Sep;77(4):735-747. doi: 10.1007/s11418-023-01715-9. Epub 2023 Jun 22. PMID: 37347409.
In vitro protocol:
1. Elsawy H, Rajendran P, Sedky AM, Alfwuaires M. Ruscogenin Protects Against Deoxynivalenol-Induced Hepatic Injury by Inhibiting Oxidative Stress, Inflammation, and Apoptosis Through the Nrf2 Signaling Pathway: An In vitro Study. Saudi J Med Med Sci. 2022 Sep-Dec;10(3):207-215. doi: 10.4103/sjmms.sjmms_725_21. Epub 2022 Aug 22. PMID: 36247053; PMCID: PMC9555037. 2. Song Z, Xiang X, Li J, Deng J, Fang Z, Zhang L, Xiong J. Ruscogenin induces ferroptosis in pancreatic cancer cells. Oncol Rep. 2020 Feb;43(2):516-524. doi: 10.3892/or.2019.7425. Epub 2019 Dec 10. PMID: 31894321; PMCID: PMC6967081.
In vivo protocol:
1. Zhang S, Yu Y, Sheng M, Chen X, Wu Q, Kou J, Chen G. Ruscogenin timing administration mitigates cerebral ischemia-reperfusion injury through regulating circadian genes and activating Nrf2 pathway. Phytomedicine. 2023 Aug 20;120:155028. doi: 10.1016/j.phymed.2023.155028. Epub ahead of print. PMID: 37659295. 2. Huang J, Zhou J, Dai Y, Liu Y, Li F, Gong S, Zhang Y, Kou J. Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways. J Nat Med. 2023 Sep;77(4):735-747. doi: 10.1007/s11418-023-01715-9. Epub 2023 Jun 22. PMID: 37347409.
1: Qi JY, Jin YC, Wang XS, Yang LK, Lu L, Yue J, Yang F, Liu YS, Jiang YL, Song DK, Lv T, Li XB, Zhang K, Liu SB. Ruscogenin Exerts Anxiolytic-Like Effect via Microglial NF-κB/MAPKs/NLRP3 Signaling Pathways in Mouse Model of Chronic Inflammatory Pain. Phytother Res. 2024 Sep 12. doi: 10.1002/ptr.8325. Epub ahead of print. PMID: 39267167. 2: Xu WK, Zhao CX, Yang XW, Chen YG, Long LP, Yan YF, Guo K, Li SH, Liu Y. Characterization of a glycosyltransferase from Paris polyphylla for application in biosynthesis of rare ophiopogonins and ginsenosides. Phytochemistry. 2024 Sep;225:114173. doi: 10.1016/j.phytochem.2024.114173. Epub 2024 Jun 6. PMID: 38851474. 3: Li J, Wu H, Zhou J, Jiang R, Zhuo Z, Yang Q, Chen H, Sha W. Ruscogenin Attenuates Ulcerative Colitis in Mice by Inhibiting Caspase-1-Dependent Pyroptosis via the TLR4/NF-κB Signaling Pathway. Biomedicines. 2024 Apr 30;12(5):989. doi: 10.3390/biomedicines12050989. PMID: 38790951; PMCID: PMC11117655. 4: Wang RY, Wang MG, Tang HZ, Du H, Luo Y, Li Q, Zhang XH, Fu J, Lv CZ. The Protective Effects of Ruscogenin Against Lipopolysaccharide-Induced Myocardial Injury in Septic Mice. J Cardiovasc Pharmacol. 2024 Aug 1;84(2):175-187. doi: 10.1097/FJC.0000000000001563. PMID: 38547523. 5: Xie G, Tong F, Xu M, Shu Y, Li Z. DT-13 inhibits the proliferation of pancreatic cancer by inducing apoptosis via AMPK-mTOR signaling. Biochem Biophys Res Commun. 2024 Feb 5;695:149451. doi: 10.1016/j.bbrc.2023.149451. Epub 2023 Dec 30. PMID: 38176173. 6: Alotaibi MO, Alotaibi NM, Alwaili MA, Alshammari N, Adnan M, Patel M. Natural sapogenins as potential inhibitors of aquaporins for targeted cancer therapy: computational insights into binding and inhibition mechanism. J Biomol Struct Dyn. 2024 Jan 4:1-22. doi: 10.1080/07391102.2023.2299743. Epub ahead of print. PMID: 38174738. 7: Ruan Q, Wang C, Zhang Y, Sun J. Ruscogenin attenuates cartilage destruction in osteoarthritis through suppressing chondrocyte ferroptosis via Nrf2/SLC7A11/GPX4 signaling pathway. Chem Biol Interact. 2024 Jan 25;388:110835. doi: 10.1016/j.cbi.2023.110835. Epub 2023 Dec 18. PMID: 38122922. 8: Zhang S, Yu Y, Sheng M, Chen X, Wu Q, Kou J, Chen G. Ruscogenin timing administration mitigates cerebral ischemia-reperfusion injury through regulating circadian genes and activating Nrf2 pathway. Phytomedicine. 2023 Nov;120:155028. doi: 10.1016/j.phymed.2023.155028. Epub 2023 Aug 20. PMID: 37659295. 9: Liu JC, Zhao QF, Zhang L, Yu BY, Li F, Kou JP. Ruscogenin Alleviates Myocardial Ischemia via Myosin IIA-Dependent Mitochondrial Fusion and Fission Balance. Am J Chin Med. 2023;51(7):1879-1904. doi: 10.1142/S0192415X23500830. Epub 2023 Aug 31. PMID: 37650421. 10: Li C, Liu Q, Chen Q, Liu P, Wang D, Yang R, Liu Q. Effects of Chinese Medicine on Pyroptosis in Coronary Heart Disease. Am J Chin Med. 2023;51(7):1653-1673. doi: 10.1142/S0192415X23500751. Epub 2023 Aug 30. PMID: 37646141. 11: Huang J, Zhou J, Dai Y, Liu Y, Li F, Gong S, Zhang Y, Kou J. Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways. J Nat Med. 2023 Sep;77(4):735-747. doi: 10.1007/s11418-023-01715-9. Epub 2023 Jun 22. PMID: 37347409. 12: Lai Q, Zhu X, Zhang L, Kou J, Liu F, Yu B, Li F. Inhibition of OAT1/3 and CMPF uptake attenuates myocardial ischemia-induced chronic heart failure via decreasing fatty acid oxidation and the therapeutic effects of ruscogenin. Transl Res. 2023 Nov;261:1-15. doi: 10.1016/j.trsl.2023.06.001. Epub 2023 Jun 12. PMID: 37315712. 13: Huang H, Li X, Zha D, Lin H, Yang L, Wang Y, Xu L, Wang L, Lei T, Zhou Z, Xiao YF, Xin HB, Fu M, Qian Y. SARS-CoV-2 E protein-induced THP-1 pyroptosis is reversed by Ruscogenin. Biochem Cell Biol. 2023 Aug 1;101(4):303-312. doi: 10.1139/bcb-2022-0359. Epub 2023 Mar 16. PMID: 36927169. 14: Liu Q, Lu JJ, Hong HJ, Yang Q, Wang Y, Chen XJ. Ophiopogon japonicus and its active compounds: A review of potential anticancer effects and underlying mechanisms. Phytomedicine. 2023 May;113:154718. doi: 10.1016/j.phymed.2023.154718. Epub 2023 Feb 16. PMID: 36854203. 15: Chen MH, Leong F, Gao SJ, Chen X, Lu JJ, Lin LG, Wang Y, Chen XJ. Comparison of Ophiopogon japonicus and Liriope spicata var. prolifera from Different Origins Based on Multi-Component Quantification and Anticancer Activity. Molecules. 2023 Jan 20;28(3):1045. doi: 10.3390/molecules28031045. PMID: 36770712; PMCID: PMC9920971. 16: Sahin I, Ceylan Ç, Bayraktar O. Ruscogenin interacts with DPPC and DPPG model membranes and increases the membrane fluidity: FTIR and DSC studies. Arch Biochem Biophys. 2023 Jan 1;733:109481. doi: 10.1016/j.abb.2022.109481. Epub 2022 Nov 26. PMID: 36522815. 17: Elsawy H, Rajendran P, Sedky AM, Alfwuaires M. Ruscogenin Protects Against Deoxynivalenol-Induced Hepatic Injury by Inhibiting Oxidative Stress, Inflammation, and Apoptosis Through the Nrf2 Signaling Pathway: An In vitro Study. Saudi J Med Med Sci. 2022 Sep-Dec;10(3):207-215. doi: 10.4103/sjmms.sjmms_725_21. Epub 2022 Aug 22. PMID: 36247053; PMCID: PMC9555037. 18: Wu Y, Yu X, Wang Y, Huang Y, Tang J, Gong S, Jiang S, Xia Y, Li F, Yu B, Zhang Y, Kou J. Erratum: Author correction to 'Ruscogenin alleviates LPS- triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' [Acta Pharmaceutica Sinica B 12 (2022) 1198-1212]. Acta Pharm Sin B. 2022 Jul;12(7):3198-3199. doi: 10.1016/j.apsb.2022.04.004. Epub 2022 Apr 8. Erratum for: Acta Pharm Sin B. 2022 Mar;12(3):1198-1212. doi: 10.1016/j.apsb.2021.09.017. PMID: 35865100; PMCID: PMC9293698. 19: Yuan J, Zhao D, Liu XF, Tian YG, Zhang HJ, Feng SX, Li JS. Systematic characterization of the components and molecular mechanisms of Jinshui Huanxian granules using UPLC-Orbitrap Fusion MS integrated with network pharmacology. Sci Rep. 2022 Jul 21;12(1):12476. doi: 10.1038/s41598-022-16711-4. PMID: 35864295; PMCID: PMC9304367. 20: Hu M, An S. Ruscogenin Prevents Folic Acid-Induced Acute Kidney Damage by Inhibiting Rev-erbα/β-Mediated Ferroptosis. Comput Intell Neurosci. 2022 Jul 8;2022:8066126. doi: 10.1155/2022/8066126. PMID: 35845882; PMCID: PMC9286993. 680 (2014).

View History

GW-5823

GW-5823

Itasetron

Itasetron

Pyrophosphoric acid, chloromethyl trimethyl ester

Pyrophosphoric acid, chloromethyl trimethyl ester

Butopiprine

Butopiprine

Pyraziflumid

Pyraziflumid

Octabromobisphenol-S

Octabromobisphenol-S